Cargando…

Non-Alcoholic Fatty Liver Disease: The Bile Acid-Activated Farnesoid X Receptor as an Emerging Treatment Target

Non-alcoholic fatty liver disease (NAFLD) is currently evolving as the most common liver disease worldwide. It may progress to liver cirrhosis and liver cancer and is poised to represent the most common indication for liver transplantation in the near future. The pathogenesis of NAFLD is multifactor...

Descripción completa

Detalles Bibliográficos
Autor principal:	Fuchs, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236512/ https://www.ncbi.nlm.nih.gov/pubmed/22187656 http://dx.doi.org/10.1155/2012/934396

Ejemplares similares

Role of farnesoid X receptor and bile acids in alcoholic liver disease
por: Manley, Sharon, et al.
Publicado: (2015)

Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease
por: Kim, Sun-Gi, et al.
Publicado: (2016)

Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration
por: Li, Guodong, et al.
Publicado: (2015)

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
por: Mori, Hideki, et al.
Publicado: (2022)

Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development
por: Takahashi, Shogo, et al.
Publicado: (2018)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
por: Abenavoli, Ludovico, et al.
Publicado: (2020)

Farnesoid X receptor and bile acids regulate vitamin A storage
por: Saeed, Ali, et al.
Publicado: (2019)

Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis
por: Tschuck, Juliane, et al.
Publicado: (2023)

The Status of Bile Acids and Farnesoid X Receptor in Brain and Liver of Rats with Thioacetamide-Induced Acute Liver Failure
por: Czarnecka, Anna Maria, et al.
Publicado: (2020)

Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis
por: Li, Hongshan, et al.
Publicado: (2020)

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor
por: She, Jianglian, et al.
Publicado: (2022)

AKR1B7 Is Induced by the Farnesoid X Receptor and Metabolizes Bile Acids
por: Schmidt, Daniel R., et al.
Publicado: (2011)

A novel role for farnesoid X receptor in the bile acid‐mediated intestinal glucose homeostasis
por: Zhao, Long, et al.
Publicado: (2020)

Regulation of Chromatin Accessibility by the Farnesoid X Receptor Is Essential for Circadian and Bile Acid Homeostasis In Vivo
por: Hassan, Haider M., et al.
Publicado: (2022)

Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases
por: Festa, Carmen, et al.
Publicado: (2017)

Bile Diversion Improves Metabolic Phenotype Dependent on Farnesoid X Receptor (FXR)
por: Pierre, Joseph F., et al.
Publicado: (2019)

Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
por: Mueller, Michaela, et al.
Publicado: (2015)

Pharmacological Activation of the Bile Acid Nuclear Farnesoid X Receptor Is Feasible in Patients with Quiescent Crohn's Colitis
por: van Schaik, Fiona D. M., et al.
Publicado: (2012)

Bile Acids Induce Cdx2 Expression Through the Farnesoid X Receptor in Gastric Epithelial Cells
por: Xu, Yingji, et al.
Publicado: (2010)

Polyphenol-induced improvements in glucose metabolism are associated with bile acid signaling to intestinal farnesoid X receptor
por: Tveter, Kevin M, et al.
Publicado: (2020)

Psyllium Fiber Protects Against Colitis Via Activation of Bile Acid Sensor Farnesoid X Receptor
por: Bretin, Alexis, et al.
Publicado: (2023)

Enhanced Alcoholic Liver Disease in Mice with Intestine-specific Farnesoid X Receptor Deficiency
por: Huang, Mingxing, et al.
Publicado: (2020)

β-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids via Farnesoid X Receptor and Constitutive Androstane Receptor
por: Klag, Thomas, et al.
Publicado: (2018)

Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome
por: Pereira-Fantini, Prue M., et al.
Publicado: (2017)

Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease
por: Mouzaki, Marialena, et al.
Publicado: (2016)

Bile acids and sphingolipids in non-alcoholic fatty liver disease
por: Jackson, Kaitlyn G., et al.
Publicado: (2022)

Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury
por: Petrescu, Anca D., et al.
Publicado: (2021)

Effects and mechanism of the bile acid (farnesoid X) receptor on the Wnt/β-catenin signaling pathway in colon cancer
por: Mao, Jiayu, et al.
Publicado: (2020)

Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease
por: Kim, Hyejin, et al.
Publicado: (2023)

Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich‐cultured human hepatocytes
por: Zhang, Yuanyuan, et al.
Publicado: (2017)

Farnesoid X receptor contributes to oleanolic acid‐induced cholestatic liver injury in mice
por: Feng, Hong, et al.
Publicado: (2022)

Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease
por: Traussnigg, Stefan, et al.
Publicado: (2020)

Bile Acids Elevated in Chronic Periaortitis Could Activate Farnesoid-X-Receptor to Suppress IL-6 Production by Macrophages
por: Cao, Shan, et al.
Publicado: (2021)

Duodenal-jejunal bypass reduces serum ceramides via inhibiting intestinal bile acid-farnesoid X receptor pathway
por: Cheng, Zhi-Qiang, et al.
Publicado: (2022)

Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets
por: Unsworth, Amanda J., et al.
Publicado: (2017)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Targeting the ileal bile salt transporter in the treatment of non-alcoholic fatty liver disease
por: Jansen, Peter L. M.
Publicado: (2021)

Bile acids regulate hepatic gluconeogenic genes and farnesoid X receptor via Gα(i)-protein-coupled receptors and the AKT pathway
por: Cao, Risheng, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ekmbvukbvuvp1qdn3j1mue9vhg